New possibilities for potentiating the effects of antidepressants of the group of selective serotonin reuptake inhibitors by the regulatory peptide Selank in the treatment of anxiety and depressive disorders


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The objective of the investigation was to study the abilities of Selank, a synthesized analogue of the endogenous immunity regulator taftcin, to augment the treatment of anxiety and depressive disorders in the first two weeks of taking the antidepressant (enhancement of the efficacy of the antidepressant of the group of selective serotonin reuptake inhibitors).

Full Text

Restricted Access

About the authors

V. Verbenko

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

Email: vverbenko@mail.ru

T. Shakina

S.I. Georgievsky Medical Academy, V.I. Vernadsky Crimean Federal University

References

  1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Washington, DC: American Psychiatric Association; 2010. URL: http://psychiatryonline.org/content.aspx?book id=28§ionid=1667485
  2. Thase M. Translating Clinical Science Into Effective Therapies // J. Clin. Psychiatry. - 2014; 75 (5): e11. doi: 10.4088/JCP.13048tx1c.
  3. Иванец Н.Н., Кинкулькина М.А., Авдеева Т.И. и др. Повышение эффективности психофармакотерапии поздних депрессий: комбинация и замена антидепрессантов // Журнал неврологии и психиатрии. - 2016; 116 (2): 43-51
  4. The President’s New Freedom Commission on Mental Health. Achieving the Promise: Transforming Mental Health Care in America, Final Report. Rockville, MD: US Department of Health and Human Services: 2003. USDHHS Publication No.SMA-03-3832. URL: http://store.samhsa.gov/product/Achieving-the-Promise-Transforming-Mental-Health-Care-in-America-Executive-Summary/SMA03-3831.
  5. Montgomery S. Is there a role for switching antidepressants in treatment-resistant depression? In: Kasper S., Montgomery M., eds. Treatment-Resistant Depression. 1st ed. / Hoboken, NJ: Wiley-Blackwell, 2013.
  6. Licht R., Qvitzau S. Treatment strategies in patients with major depression not responding to first-line sertraline treatment: a randomised study of extended duration of treatment, dose increase or mianserin augmentation // Psychopharmacology (Berl). - 2002; 161 (2): 143-51.
  7. Schweizer E., Rynn M., Mandos L. et al. The antidepressant effect of sertraline is not enhanced by dose titration: results from an outpatient clinical trial // Int. Clin. Psychopharmacol. - 2001; 16 (3): 137-43.
  8. Papakostas G., Fava M., Thase M. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches // Biol. Psychiatry. - 2008; 63 (7): 699-704.
  9. Souery D., Serretti A., Calati R. et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression // J. Clin. Psychopharmacol. - 2011; 31 (4): 512-6.
  10. Haubmann R., Bauer M. Lithium, thyroid hormones and further augmentation strategies in treatment-resistant depression. In: Kasper S., Montgomery M., eds. Treatment-Resistant Depression. 1st ed. / Hoboken, NJ: Wiley-Blackwell, 2013.
  11. Trivedi M., Fava M., Wisniewski S. et al. STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression // N. Engl. J. Med. - 2006; 354 (12): 1243-52.
  12. Nelson J., Papakostas G. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials // Am. J. Psychiatry. - 2009; 166 (9): 980-91.
  13. Kasper S., Akimova E. The role of atypical antipsychotics in inadequate response and treatment-resistant depression. In: Kasper S., Montgomery M., eds. Treatment-Resistant Depression. 1st ed. / Hoboken, NJ: Wiley-Blackwell, 2013.
  14. Nutt D., Demyttenaere K., Janka Z. et al. The other face of depression, reduced positive affect: the role of catecholamines in causation and cure // J. Psychopharmacol. - 2007; 21 (5): 461-71.
  15. Pehrson A., Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction // CNS Spectr. - 2013; 1: 1-13.
  16. Fabbri C., Porcelli S., Serretti A. Genetics of treatment-resistant depression. In: Kasper S., Montgomery M., eds. Treatment-Resistant Depression. 1st ed. / Hoboken, NJ: Wiley-Blackwell, 2013.
  17. Zarate C., Duman R., Liu G. et al. New paradigms for treatment-resistant depression // Ann. NY Acad. Sci. - 2013; 1292 (1): 21-31.
  18. Мясоедов Н.Ф., Иллариошкин С.Н., Журавлева Е.Ю. и др. Пептидная нейропротекция препаратом «Селанк, капли назальные 0,15%» у пациентов на ранней стадии с болезнью Паркинсона // Вестн. неврол., психиат. и нейрохир. - 2013; 6: 86-95
  19. Verbenko G., Verbenko V. The effectiveness of selank in the treatment of adjustment disorder // Psychosomatic Medicine and General Practice. - 2018; 3 (1). doi: 10.26766/pmgp.v3i1.86.
  20. Вербенко В.А. Эффективность аналога эндогенного пептида тафтцина при терапии расстройств пищевого поведения // Лечение и профилактика. -2017; 3: 49-57
  21. Зозуля А.А., Незнамов Г.Г., Сюняков Т.С. и др. Эффективность и возможные механизмы действия нового пептидного анксиолитика Селанка при терапии генерализованного тревожного расстройства и неврастении // Журн. неврологии и психиатрии им. С.С. Корсакова. - 2008; 108 (4): 38-49

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Russkiy Vrach Publishing House